Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimetoran in active cutaneous lupus erythematosus
NCT07881120Phase 3Recruiting
- Sponsor
- Beeline Medicines
- Start
- Oct 2026
- Primary completion
- Apr 2030
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of afimetoran in cutaneous lupus erythematosus (CLE) (3 arms), sponsored by Beeline Medicines. Primary endpoints: Percent change from baseline in CLASI-A total score at 24 weeks and Proportion of participants achieving a CLASI-70 response at 24 weeks. Started Oct 2026; status: recruiting.
02
Drugs
afimetoran
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT07881120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881120.